We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

The World Bank Group is partnering with the African Development Bank and other partners on Mission 300, an ambitious initiative to connect 300 million people to electricity in Sub-Saharan Africa by ...

The company's flagship products include Eylea for eye diseases and Dupixent for various inflammatory conditions. In the second quarter of 2024, Regeneron demonstrated strong performance ...

Next to the original 5.56mm NATO/223, the 300 AAC Blackout (BLK for short) is the most popular chambering for the AR-15 platform, and, as a result, manufacturers now pump out a wide variety of 300 ...

GE Hitachi Nuclear Energy (GEH), a business of GE Vernova, has joined the coalition of utility companies that are working to accelerate the deployment of BWRX-300 small modular reactors in the ...

In the market for a deal on a new car? If you can stretch to £300 per month, you’ll have a veritable treasure trove of finance deals to pick from. The sheer number of models that fall into this range ...

300 is a 2007 fantasy war movie directed by Zack Snyder, which is based on a graphic novel of the same name by Frank Miller. The graphic novel and the movie tell the true story of King Leonidas I ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Doesn’t matter that Regeneron is working on 40 different compounds, many of which could be blockbusters, doesn’t matter if their breakthrough drug Dupixent is indicated for seven gigantic ...

Your browser does not support the audio element. After a few recent spy sightings, the Apache RTX 300 adventure bike has been leaked from the show floor at the ...

The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic colorectal cancer, but in its approval announcement, the FDA pointed to ...